```html
BBIO (BridgeBio Pharma) - Comprehensive Stock & Company Analysis
BBIO: BridgeBio Pharma, Inc.
Key Finding: BridgeBio Pharma (BBIO) has emerged as a high-performing commercial-stage biotech with strong revenue growth from its flagship Attruby product and multiple late-stage pipeline catalysts driving a near-doubling of its stock price over the past year as of July 2026.
Company Overview
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases and cancers.
- Headquarters: Palo Alto, California
- Founded: 2015
- Employees: Approximately 837 (as of latest reports)
- Business Model: Hub-and-spoke approach targeting Mendelian (genetic) diseases with high unmet need; multiple approved and late-stage assets.
- Key Approved Products: Attruby (acoramidis) – next-generation TTR stabilizer for ATTR-CM; NULIBRY (fosdenopterin) for molybdenum cofactor deficiency.
Interpretation: The company has successfully transitioned from clinical-stage to commercial, with Attruby generating substantial revenue in 2025.
Company History
- 2015: Founded by Neil Kumar, Ph.D., and colleagues with a mission to address genetic diseases through targeted therapies.
- 2019: Initial Public Offering (IPO) on NASDAQ.
- 2020s: Advanced pipeline including multiple Phase 3 programs; secured partnerships (e.g., Bayer, Alexion, Novartis, Stanford).
- 2024-2025: FDA approval and commercial launch of Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM).
- 2026: Continued pipeline progress with positive PROPEL 3 data for infigratinib and regulatory submissions for additional assets.
All timeline items are factual events reported in company disclosures and financial news.
Recent News (2026 Highlights)
- July 2026: Stock surged ~15% intraday on positive catalysts including analyst upgrades and trial momentum. Market reaction reflects strong sentiment around commercial and pipeline progress.
- July 1-2, 2026: Raised $1 billion in preferred equity financing to accelerate launches; announced kidney-protective effects data for acoramidis.
- June 28, 2026: PROPEL 3 Phase 3 trial results for oral infigratinib in achondroplasia published in New England Journal of Medicine.
- Early 2026: Q4/FY 2025 results showed $502.1M full-year revenue (primarily from Attruby); Q1 2026 revenue reached $194.5M.
- May-June 2026: FDA acceptance/priority review for BBP-418 (LGMD2I); multiple analyst Buy ratings with price targets up to $111.
Stock Performance (as of early July 2026 data)
| Metric |
Value |
Notes |
| Recent Price (July 9, 2026) |
~$89–$93 (intraday surge) |
Previous close ~$78.33; +14–16% daily move common in reports |
| 52-Week Range |
$42.09 – $93.42 |
Significant recovery and new highs |
| Market Cap |
~$15.3B – $18B |
Large-cap biotech classification |
| YTD Return |
~18.72% |
Outperformed S&P 500 (~10.12%) |
| 1-Year Return |
~97.5% |
Strong outperformance vs S&P 500 (~20.36%) |
| 3-Year Return |
~437.66% |
Exceptional long-term gains |
Comparison Table: BBIO vs S&P 500
| Period |
BBIO |
S&P 500 |
| YTD |
18.72% |
10.12% |
| 1-Year |
97.50% |
20.36% |
| 3-Year |
437.66% |
71.37% |
| 5-Year |
41.51% |
72.52% |
Interpretation: BBIO has significantly outperformed broader markets in recent periods, driven by commercial success and pipeline de-risking, though biotech stocks remain volatile.
Uncertainties: Stock prices fluctuate rapidly; figures represent snapshots from search data around July 9, 2026.
Links for More Information
Data Limitations & Assumptions:
• All financial and stock data is based on publicly available web search results as of July 9–10, 2026. Real-time prices may differ.
• Biotech stocks are highly volatile; performance figures are historical snapshots and not predictive.
• Revenue and pipeline status reflect company-reported figures and regulatory announcements.
• No forward-looking financial advice is provided. Consult official filings (SEC) and licensed advisors for investment decisions.
• Assumptions: Data sourced from reputable financial platforms (Yahoo Finance, company IR) and aggregated news reports.
Generated on July 10, 2026 | Information compiled from multiple public sources
```